WO2006003518A3 - 6-phosphorylcholine-n-acetyl-d-galactosamine conjugate molecules and their use in vaccinal, therapeutic and diagnostic applications against bacterial infection of the respiratory tract - Google Patents

6-phosphorylcholine-n-acetyl-d-galactosamine conjugate molecules and their use in vaccinal, therapeutic and diagnostic applications against bacterial infection of the respiratory tract Download PDF

Info

Publication number
WO2006003518A3
WO2006003518A3 PCT/IB2005/002316 IB2005002316W WO2006003518A3 WO 2006003518 A3 WO2006003518 A3 WO 2006003518A3 IB 2005002316 W IB2005002316 W IB 2005002316W WO 2006003518 A3 WO2006003518 A3 WO 2006003518A3
Authority
WO
WIPO (PCT)
Prior art keywords
respiratory tract
phosphorylcholine
acetyl
bacterial infection
chop
Prior art date
Application number
PCT/IB2005/002316
Other languages
French (fr)
Other versions
WO2006003518A2 (en
Inventor
Sylvie Bay
Pierre Lafaye
Patrick England
Jean-Michel Alonso
Valerie Huteau
Mireille Leduc
Farida Nato
Muhamed-Kheir Taha
Original Assignee
Pasteur Institut
Centre Nat Rech Scient
Univ Paris 11 Sud
Sylvie Bay
Pierre Lafaye
Patrick England
Jean-Michel Alonso
Valerie Huteau
Mireille Leduc
Farida Nato
Muhamed-Kheir Taha
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut, Centre Nat Rech Scient, Univ Paris 11 Sud, Sylvie Bay, Pierre Lafaye, Patrick England, Jean-Michel Alonso, Valerie Huteau, Mireille Leduc, Farida Nato, Muhamed-Kheir Taha filed Critical Pasteur Institut
Publication of WO2006003518A2 publication Critical patent/WO2006003518A2/en
Publication of WO2006003518A3 publication Critical patent/WO2006003518A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56944—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/104—Pseudomonadales, e.g. Pseudomonas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/21—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Pseudomonadaceae (F)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/22—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Neisseriaceae (F), e.g. Acinetobacter
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/285—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The present invention relates to carbohydrate-phosphorylcholine conjugate molecule, and more particularly to phosphorylcholine-N-acetyl-D-galactosamine molecules and their use for treating and/or preventing a bacterial infection of the respiratory tract. More specifically, in this present application, the inventors aimed at raising high-affinity antibodies against ChoP preferably in its bacterial context in order to target several pathogens of the respiratory tract. By mimicking the S. pneumoniae model, the inventors preferably synthesized two carbohydrate-ChoP (GalNAc-ChoP) protein conjugates and showed that these immunogens induce hapten-specific antibodies which recognize two major bacterial pathogens of the respiratory tract : such as a Gram-positive bacterium, S. pneumoniae, and a Gram-negative bacterium, N. meningitidis.
PCT/IB2005/002316 2004-06-30 2005-06-30 6-phosphorylcholine-n-acetyl-d-galactosamine conjugate molecules and their use in vaccinal, therapeutic and diagnostic applications against bacterial infection of the respiratory tract WO2006003518A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA2472818 2004-06-30
CA002472818A CA2472818A1 (en) 2004-06-30 2004-06-30 Carbohydrate-phosphorylcholine conjugate molecules and their use in vaccinal, therapeutic and diagnostic applications

Publications (2)

Publication Number Publication Date
WO2006003518A2 WO2006003518A2 (en) 2006-01-12
WO2006003518A3 true WO2006003518A3 (en) 2006-12-28

Family

ID=35589012

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2005/002316 WO2006003518A2 (en) 2004-06-30 2005-06-30 6-phosphorylcholine-n-acetyl-d-galactosamine conjugate molecules and their use in vaccinal, therapeutic and diagnostic applications against bacterial infection of the respiratory tract

Country Status (2)

Country Link
CA (1) CA2472818A1 (en)
WO (1) WO2006003518A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014213631B2 (en) * 2013-02-05 2018-03-08 Tpcera Ltd Phosphorylcholine conjugates and uses thereof
US10046021B2 (en) 2013-02-05 2018-08-14 Tpcera Ltd. Phosphorylcholine conjugates and uses thereof
US9107906B1 (en) 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
GB2622559A (en) * 2022-05-10 2024-03-27 Johan Frostegaard Compositions, methods and uses

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BAY, SYLVIE ET AL: "Phosphorylcholine-Carbohydrate-Protein Conjugates Efficiently Induce Hapten-Specific Antibodies Which Recognize Both Streptococcus pneumoniae and Neisseria meningitidis: A Potential Multitarget Vaccine against Respiratory Infections", JOURNAL OF MEDICINAL CHEMISTRY , 47(16), 3916-3919 CODEN: JMCMAR; ISSN: 0022-2623, 2004, XP002385018 *
BROWN MCKAY ET AL: "The structural basis of repertoire shift in an immune response to phosphocholine", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 191, no. 12, 19 June 2000 (2000-06-19), pages 2101 - 2111, XP002385013, ISSN: 0022-1007 *
FARO, JOSE ET AL: "Immunoresponses to Neisseria meningitidis epitopes: suppression of secondary response to phosphorylcholine is carrier specific", INFECTION AND IMMUNITY , 51(1), 224-32 CODEN: INFIBR; ISSN: 0019-9567, 1986, XP002385017 *
FISCHER WERNER ET AL: "Teichoic acid and lipoteichoic acid of Streptococcus pneumoniae possess identical chain structures: A reinvestigation of teichoic acid (C polysaccharide)", EUROPEAN JOURNAL OF BIOCHEMISTRY, vol. 215, no. 3, 1993, pages 851 - 857, XP002385015, ISSN: 0014-2956 *
KARLSSON CAMILLA ET AL: "The pneumococcal common antigen C-polysaccharide occurs in different forms. Mono-substituted or di-substituted with phosphocholine", EUROPEAN JOURNAL OF BIOCHEMISTRY, vol. 265, no. 3, November 1999 (1999-11-01), pages 1091 - 1097, XP001193753, ISSN: 0014-2956 *
WARREN MATTHEW J ET AL: "Identification and characterization of pptA: A gene involved in the phase-variable expression of phosphorylcholine on pili of Neisseria meningitidis.", INFECTION AND IMMUNITY, vol. 71, no. 12, December 2003 (2003-12-01), pages 6892 - 6898, XP002385014, ISSN: 0019-9567 *

Also Published As

Publication number Publication date
WO2006003518A2 (en) 2006-01-12
CA2472818A1 (en) 2005-12-30

Similar Documents

Publication Publication Date Title
WO2008079372A3 (en) Novel immunogenic compositions for the prevention and treatment of meningococcal disease
EP4279140A3 (en) Human antibodies against tissue factor
WO2008001224A3 (en) Polypeptides from neisseria meningitidis
WO2005014024A3 (en) Conjugates of a polymer and a protein linked by an oxime linking group
EP2348035A3 (en) Novel immunogenic compositions for the prevention and treatment of meningococcal disease
EP2535355A3 (en) Antibodies against CD38 for treatment of multiple myeloma
MXPA05011110A (en) Novel immunogenic compositions for the prevention and treatment of meningococcal disease.
WO2010139808A3 (en) Monovalent, bivalent and trivalent anti human respiratory syncytial virus (hrsv) nanobody constructs for the prevention and/or treatment of respiratory tract infections
WO2006040129A3 (en) Ubiquitin or gamma-crystalline conjugates for use in therapy, diagnosis and chromatography
WO2006108670A3 (en) Use of cd25 antibodies in immunotherapy
WO2005103081A3 (en) Human monoclonal antibodies against cd20
WO2006065553A3 (en) Glycoconjugate vaccines containing peptidoglycan
WO2009088549A3 (en) Methods of inhibiting bacterial virulence and compounds relating thereto
EA201001212A8 (en) TREATMENT OF MICROBIAL INFECTIONS
WO2009083009A3 (en) Monoclonal antibodies against cd32b
EP2886551A3 (en) Meningococcal fhbp polypeptides
WO2007007173A3 (en) Human anti-madcam antibodies
WO2009010877A3 (en) Conjugate purification
WO2008017381A8 (en) Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
WO2006003518A3 (en) 6-phosphorylcholine-n-acetyl-d-galactosamine conjugate molecules and their use in vaccinal, therapeutic and diagnostic applications against bacterial infection of the respiratory tract
WO2006009525A3 (en) P. aeruginosa mucoid exopolysaccharide specific binding peptides
WO2007138381A3 (en) Phosphonated oxazolidinones and uses thereof for the prevention and treatment of bone and joint infections
WO2006138627A3 (en) Monoclonal antibodies recognizing a coagulase-negative staphylococcal protein
WO2009053628A3 (en) Novel compounds, preparation and uses thereof
WO2006129092A3 (en) Use of bacteriophage in medicaments

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase